Cellares
PrivateLast Round
Series D
Jun 18, 2026
Est. Valuation
$1.44B
Total Funding Raised
$1.01B
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Cellares is a biotechnology company that provides integrated development and manufacturing solutions for cell therapies through its automated IDMO Smart Factory network.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Smart Manufacturing, Biotech Equipment, Warehouse Automation
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cellares Comparables
Compare Cellares with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ori Biotech | 83% | |
| Cellular Origins | 81% | |
| Miltenyi Biotec | 80% |
For institutional investors. Book with your work email.
Cellares Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 18, 2026 | ||||
| Series D | Jan 28, 2026 | ||||
| IPO | Dec 1, 2025 | ||||
| Series C | Aug 23, 2023 | ||||
| Series B | May 5, 2021 | ||||
Series A | Aug 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cellares Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series A |
| Prime Radiant Partners | Series D |
| S32 | Series C |
| Skyviews Life Science | Series B |
| Duquesne Family Office | Series D |
| Koch-ventures.com | Series C |
| EDBI | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 65% MoM, reaching 32.2K.
- Jun 18, 2026
$257M round raised
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 23, 2026
Cellares partners with Snuh to evaluate automated manufacturing for a gene-modified HSPC therapy targeting PNH on its Cell Shuttle platform in California on Sep 23rd '26.
- partners_withSep 17, 2026
Cellares partners with GenomeFrontier Therapeutics, Inc. to evaluate automated manufacturing of GenomeFrontier Therapeutics' investigational CAR-T therapy GF-CART01 on the Cell Shuttle platform in Sep '26.
- decreases_headcount_bySep 16, 2026
Cellares plans to reduce its workforce by 168 jobs in California and New Jersey after losing a large pharmaceutical customer, with the plans first announced in Aug '26.
- decreases_headcount_byAug 27, 2026
Following Bristol Myers Squibb's ended manufacturing partnership, Cellares plans to cut approximately 100 employees at its South San Francisco facility in California in Aug '26.
- has_revenueAug 10, 2026
In 2025, Cellares reports $82M in revenue.
For institutional investors. Book with your work email.
Cellares Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cellares's valuation, stock price, and market status.
Is Cellares a public or private company?
Cellares is a private company.
What is the current stock price of Cellares?
Cellares is a private company, so its shares have no public market price. Caplight tracks Cellares's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cellares worth (valuation)?
Cellares's valuation is estimated at $1.4B based on funding round data.
Can I buy Cellares stock?
Cellares shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cellares's last funding round?
Cellares's most recent funding round was Series D on June 18, 2026.
Who are the main investors in Cellares?
Key investors in Cellares include Koch-ventures.com, Eclipse Ventures, Koch Disruptive Technologies, BlackRock, Decheng Capital.
Will Cellares IPO soon?
No public IPO plans have been announced for Cellares.
How can I track Cellares secondary market activity?
Caplight tracks bids, offers, and trades in Cellares's shares on secondary markets.